2025
BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB
Dubinsky M, Schreiber S, Matsuoka K, Jairath V, Al-Bawardy B, Pellanda P, Zhu B, Bleakman A, Redondo I, Owen C, Limdi J. BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB. Inflammatory Bowel Diseases 2025, 31: s62-s63. DOI: 10.1093/ibd/izae282.147.Peer-Reviewed Original ResearchNumerical rating scalePain numerical rating scaleModified Mayo scoreMultivariate linear regression analysisInflammatory Bowel Disease QuestionnaireUnivariate analysisUlcerative colitisMayo scorePrognostic variablesAnti-IL-23p19 antibodyBaseline characteristics of patientsAnti-IL-23p19Linear regression analysisPhase 3 trialRegression analysisCharacteristics of patientsUrgency Numeric Rating ScaleBristol Stool ScaleMultivariate regression analysisPost hoc analysisUnivariate analysis of associationPrognostic factorsDisease extentBaseline characteristicsMirikizumabMapping the Ulcerative Colitis Patient Journey in Saudi Arabia from Healthcare Professionals’ Perspective: A Cross-Sectional Non-Interventional Study
Azzam N, Mosli M, Almutairdi A, Alghamdi M, Meeralam Y, Alolimi K, Arsalan M, Al-Bawardy B. Mapping the Ulcerative Colitis Patient Journey in Saudi Arabia from Healthcare Professionals’ Perspective: A Cross-Sectional Non-Interventional Study. Journal Of Clinical Medicine 2025, 14: 1621. PMID: 40095549, PMCID: PMC11899997, DOI: 10.3390/jcm14051621.Peer-Reviewed Original ResearchComputer-assisted personal interviewsQuality of lifeGeneral practitionersPatient journeyTreatment goalsHealthcare professionals' perspectivesTNF-a inhibitorsInternal medicine physiciansBurden of ulcerative colitisUlcerative colitisClinical remissionImprovement of quality of lifeUC patientsOral systemic steroidsHealthcare professionalsSaudi ArabiaTNF-aPhysician responsesSurvey domainsYears of experienceProfessional perspectivesQuantitative interviewsTreating gastroenterologistImprove accessMedicine physiciansColorectal Neoplasia in Inflammatory Bowel Disease
Al Sulais E, AlAmeel T, Alenzi M, Shehab M, AlMutairdi A, Al-Bawardy B. Colorectal Neoplasia in Inflammatory Bowel Disease. Cancers 2025, 17: 665. PMID: 40002259, PMCID: PMC11853504, DOI: 10.3390/cancers17040665.Peer-Reviewed Original ResearchRisk of colonic neoplasiaColonic neoplasiaInflammatory bowel diseaseConcomitant primary sclerosing cholangitisRisk factorsMultiple risk factorsColorectal neoplasiaBowel diseaseHigh-risk featuresIncreased riskPrimary sclerosing cholangitisColonic Crohn's diseaseColonic dysplasiaDisease extentSclerosing cholangitisRiskCrohn's diseaseNeoplasiaUlcerative colitisDiseaseSurveillancePatientsColorectalEpidemiologyBASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB
Dubinsky M, Schreiber S, Matsuoka K, Jairath V, Al-Bawardy B, Pellanda P, Zhu B, Bleakman A, Redondo I, Owen C, Limdi J. BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB. Gastroenterology 2025, 168: s88-s89. DOI: 10.1053/j.gastro.2025.01.212.Peer-Reviewed Original ResearchP1216 Mapping the Ulcerative Colitis patient journey in Saudi Arabia from healthcare professionals' perspective: A cross-sectional non-interventional study
Azzam N, Mosli M, Almutairdi A, Alghamdi M, Meeralam Y, Alolimi K, Arsalan M, Al-Bawardy B. P1216 Mapping the Ulcerative Colitis patient journey in Saudi Arabia from healthcare professionals' perspective: A cross-sectional non-interventional study. Journal Of Crohn's And Colitis 2025, 19: i2198-i2200. DOI: 10.1093/ecco-jcc/jjae190.1390.Peer-Reviewed Original ResearchComputer-assisted personal interviewsPatient journeyLack of awarenessTNF-a inhibitorsPatient-related barriersHealthcare professionals' perspectivesInstitutional review boardTreatment goalsBurden of ulcerative colitisFear of long-term side effectsSecond-line treatmentFirst-line treatmentQuality of lifeQuality of life improvementTNF-aHealthcare professionalsManagement of adultsSurvey domainsYears of experienceUlcerative colitisProfessional perspectivesOptimal careQuantitative interviewsImprove accessEndoscopic remissionP0442 Prevalence and Impact of E-cigarettes on Disease Outcomes in Patients with Inflammatory Bowel Disease
Almuhaya H, Alashkar R, Alsebaai D, Albadawi N, Almutairdi A, Attamimi M, Desai S, Al-Bawardy B. P0442 Prevalence and Impact of E-cigarettes on Disease Outcomes in Patients with Inflammatory Bowel Disease. Journal Of Crohn's And Colitis 2025, 19: i951-i951. DOI: 10.1093/ecco-jcc/jjae190.0616.Peer-Reviewed Original ResearchTraditional cigarette smokingPrevalence of EC useClinical outcomesCrohn's diseaseEC useAdvanced therapiesIBD patientsCigarette smokingUlcerative colitisElectronic cigarettesPenetrating diseaseComposite outcomeIBD-unclassifiedHistory of intestinal surgeryAssociated with male sexFollow-up durationImpact of e-cigarettesDiagnosis of IBDCross-sectional studyCigarette smoking historyInflammatory bowel diseaseNo significant differencePerianal diseaseIBD registrySurgical interventionP1260 Demographics and Clinical Characteristics of Inflammatory Bowel Disease in the Middle East and North Africa : A Multi-Nation Cross-sectional (MIRAGE) Study
Shehab M, Azzam N, Al-Bawardy B, Abid S, Bashandi A, AlShihri R, Mukhtar M, Saadah O, Alharbi O, Al-Darmaki A, Al Harthi S, Al-Ejji K, Ayash A, Al sahli A, Khamees N, Salem O, Mohamed E, Maher M, Daba G, Helal A, Alnassar M, Alfadhli A, Mosli M. P1260 Demographics and Clinical Characteristics of Inflammatory Bowel Disease in the Middle East and North Africa : A Multi-Nation Cross-sectional (MIRAGE) Study. Journal Of Crohn's And Colitis 2025, 19: i2280-i2281. DOI: 10.1093/ecco-jcc/jjae190.1434.Peer-Reviewed Original ResearchInflammatory bowel disease patientsMiddle East and North Africa regionEpidemiology of inflammatory bowel diseaseInflammatory bowel diseaseJournal of EpidemiologyInflammatory bowel disease cohortPrevalence of inflammatory bowel diseaseClinical characteristics of inflammatory bowel diseaseCharacteristics of inflammatory bowel diseaseCD patientsBowel diseaseIBD-related surgeryChi-square testMulti-national studyInflammatory bowel disease centerMiddle East and North AfricaCrohn's diseaseRising prevalenceUlcerative colitisFisher's exact testLeft-sided colitisDemographic characteristicsKingdom of Saudi ArabiaMiddle Eastern patientsIBD-UEffectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis
Sannaa W, Almasry M, Peedikayil M, Grimshaw A, Attamimi M, AlMutairdi A, Al-Bawardy B. Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therapeutic Advances In Gastroenterology 2025, 18: 17562848241312766. PMID: 39802627, PMCID: PMC11719443, DOI: 10.1177/17562848241312766.Peer-Reviewed Original ResearchOral vancomycin therapyPrimary sclerosing cholangitisIBD-PSCInflammatory bowel diseasePooled analysisClinical responseSclerosing cholangitisEpisodes of acute cholangitisFavorable side effect profilePooled analysis of studiesSystematic reviewInflammatory bowel disease associated with primary sclerosing cholangitisSide effect profileLong-term safetyClinical response/remissionVancomycin therapyOral vancomycinClinical remissionEndoscopic remissionAcute cholangitisMedian durationImmunosuppressive agentsNo episodesConcomitant treatmentEffect profileAuthors' comment on: effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.
Al-Bawardy B, Quraishi M. Authors' comment on: effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therapeutic Advances In Gastroenterology 2025, 18: 17562848251328606. PMID: 40144790, PMCID: PMC11938434, DOI: 10.1177/17562848251328606.Peer-Reviewed Original Research
2024
A bibliometric analysis of inflammatory bowel disease research in the Arab world.
AlMuhaidib S, Bzeizi K, AlAmeel T, Mosli M, Khoja B, Barakeh D, Alomaim W, Alqahtani S, Al-Bawardy B. A bibliometric analysis of inflammatory bowel disease research in the Arab world. Saudi Journal Of Gastroenterology 2024 PMID: 39660608, DOI: 10.4103/sjg.sjg_303_24.Peer-Reviewed Original ResearchCitation impactPublication countsBibliometric analysisResearch outputPrevalence of inflammatory bowel diseaseInflammatory bowel diseaseClarivate AnalyticsIncidence rateResearch impactInstitute for Health MetricsCitationsIncidence trendsHealth metricsIBD incidenceRising prevalenceArab countriesGlobal ratingImproving research impactIBD researchInflammatory bowel disease researchSpearman correlationPrevalenceClarivateMetricsOutputS1165 Prevalence and Risk Factors for Ulcerative Colitis Flares After Colonoscopy
Khan F, Chung S, Kadhim B, Ameyaw P, Fetene J, Dominguez-Diaz A, Al-Bawardy B, Levy A, Proctor D, Gaidos J. S1165 Prevalence and Risk Factors for Ulcerative Colitis Flares After Colonoscopy. The American Journal Of Gastroenterology 2024, 119: s827-s828. DOI: 10.14309/01.ajg.0001034028.79665.88.Peer-Reviewed Original ResearchS1497 Prevalence and Impact of Zinc Deficiency on Clinical Outcomes in Inflammatory Bowel Disease
Almuhaya H, Alsalamah R, Sallam A, Alonazy A, AlAwwad A, Mohamed G, Almutairdi A, Attamimi M, Al-Bawardy B. S1497 Prevalence and Impact of Zinc Deficiency on Clinical Outcomes in Inflammatory Bowel Disease. The American Journal Of Gastroenterology 2024, 119: s1083-s1084. DOI: 10.14309/01.ajg.0001035356.00119.f9.Peer-Reviewed Original ResearchS1498 Prevalence and Outcomes of Active and Latent Tuberculosis Among Patients With Inflammatory Bowel Disease (IBD) in an Endemic Region
Alayed M, Alrasheed A, Alenezi M, Binsalmah I, Almutairdi A, Attamimi M, Al-Bawardy B. S1498 Prevalence and Outcomes of Active and Latent Tuberculosis Among Patients With Inflammatory Bowel Disease (IBD) in an Endemic Region. The American Journal Of Gastroenterology 2024, 119: s1084-s1085. DOI: 10.14309/01.ajg.0001035360.73644.fd.Peer-Reviewed Original ResearchS1066 Outcomes of Isolated Recurrent, Persistent Complex Perianal Fistulas Without Luminal Crohn’s Disease: A Case Series of 24 Patients
Fiske H, Tse C, Al-Bawardy B, Magavi P, Konijeti G, Mao E, Fine S, Parian A, Lazarev M, Shah S. S1066 Outcomes of Isolated Recurrent, Persistent Complex Perianal Fistulas Without Luminal Crohn’s Disease: A Case Series of 24 Patients. The American Journal Of Gastroenterology 2024, 119: s752-s756. DOI: 10.14309/01.ajg.0001033632.76152.4b.Peer-Reviewed Original ResearchClinical Course of Isolated Recurrent, Persistent Complex Perianal Fistulas Without Luminal Crohn’s Disease: A Multicenter Case Series of 24 Patients
Fiske H, Tse C, Al-Bawardy B, Magavi P, Konijeti G, Mao E, Fine S, Parian A, Lazarev M, Shah S. Clinical Course of Isolated Recurrent, Persistent Complex Perianal Fistulas Without Luminal Crohn’s Disease: A Multicenter Case Series of 24 Patients. Crohn's & Colitis 360 2024, 6: otae065. PMID: 39679162, PMCID: PMC11645454, DOI: 10.1093/crocol/otae065.Peer-Reviewed Original ResearchComplex perianal fistulasMulticenter case seriesPerianal fistulasIntensive surgical interventionClinical courseCrohn's diseaseCase seriesSurgical interventionPresumptive diagnosis of Crohn's diseaseClinical course of patientsEvidence of inflammatory bowel diseaseRetrospective multicenter case seriesPresentation of Crohn's diseaseLuminal Crohn's diseaseCourse of patientsOutcomes of patientsDiagnosis of Crohn's diseaseMedical-surgical approachInflammatory bowel diseaseComplex fistulasLuminal inflammationFistula closureCryptoglandular fistulasSurgical therapyBiologic therapyRisankizumab for Ulcerative Colitis
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel J, Parkes G, Peyrin-Biroulet L, D’Haens G, Hisamatsu T, Siegmund B, Wu K, Boland B, Melmed G, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan W, Pivorunas V, Sanchez Gonzalez Y, D’Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus E, Balderramo D, Goncalves S, Lasa J, Novillo A, Ruffinengo O, Heeren S, Reinisch W, Baert F, Bossuyt P, Colard A, Dewit O, Ferrante M, Franchimont D, Louis E, Rahier J, Francesconi C, Kaiser Junior R, Parra R, Sassaki L, Penchev P, Stanchev D, Atkinson K, Beaton M, Bessissow T, Greenbloom S, Lachance J, Lim A, Panaccione R, Samson J, Shulman S, Siffledeen J, Alfaro I, Valenzuela C, Walsen G, An P, Cao Q, Chen Y, Chen Y, Gao X, Hou X, Hu N, Li Y, Liu F, Liu M, Lungen L, Ran Z, Tang T, Wang X, Yang S, Zhan Q, Zhang G, Zhang H, Zhang J, Zhang X, Zhong J, Zou X, Alvarez E, Ricaurte J, Borzan V, Krznaric Z, Puljiz Z, Bortlik M, Svoboda P, Ulbrych J, Vanasek T, Kjeldsen J, Munck L, Poulsen A, Ali E, Salem O, Sawah H, Waked I, Altwegg R, FLAMANT M, Fumery M, Hebuterne X, Laharie D, Peyrin-Biroulet L, Roblin X, Treton X, Atreya R, Deppe H, Hasselblatt P, Kandulski A, Klaus J, Krause T, Kucharzik T, Mertens J, Mross M, Naumann A, Reindl W, Schiefke I, Schreiber S, Schubert S, Siegmund B, Sturm A, Bamias G, Koutroubakis I, Manolakopoulos S, Mantzaris G, Tzouvala M, Viazis N, Avni-Biron I, Goldin E, Katz L, Lahat-Zok A, Segal A, Ardizzone S, Armuzzi A, Cicala M, Colecchia A, Cosintino R, Gasbarrini A, Geccherle A, Giannini E, Gionchetti P, Luzza F, Monteleone G, Privitera A, Saibeni S, Vangeli M, Abe Y, Aoyama N, Asonuma K, Endo Y, Esaki M, Fujii T, Fukuda K, Hirai F, Hisanaga Y, Horiki N, Iguchi M, Ishigami K, Ishiguro Y, Ito H, Kakuta Y, Kamikozuru K, Kato J, Kawanishi T, Kobayashi T, Kuge H, Maemoto A, Masuda T, Matsuoka K, Matsushima K, Matsushima M, Motoya S, Nakai K, Nakajima K, Nakamura M, Nishida A, Nishikawa T, Nishimata N, Ochiai T, Ohmiya N, Ohnishi Y, Oka S, Ozeki K, Saito D, Saruta M, Sasaki M, Shimizu M, Sugimoto K, Sujino T, Suzuki T, Takatori H, Takatsu N, Takedatsu H, Takeuchi K, Tanaka H, Tokito S, Endo T, Toyokawa T, Uenoyama Y, Yamamoto T, Yamamoto T, Yasuda H, Yokoyama K, Derovs A, Pukitis A, Jonaitis L, Kazenaite E, Pinzon Te L, D'Haens G, Lutgens M, Brooker J, Gearry R, Griffiths B, Inns S, Schultz M, Eszyk J, Kierkus J, Kleczkowski D, Kopon A, Petryka R, Regula J, Romanczyk T, Rydzewska-Wyszkowska G, Sikorski P, Talarek M, Cerqueira R, Goncalves T, Lopes S, Ministro P, Portela F, Tavares H, Diculescu M, Goldis A, Seicean A, Agafina A, Edin A, Gerasimova E, Gettueva M, Kashnikov V, Pirmagomedov A, Rafalskiy V, Sharapova K, Smolyarchuk E, Varganova D, Grgov S, Jovanovic I, Svorcan P, Tarabar D, Ling K, Balaz J, Durina J, Gregus M, Laclav M, Drobne D, Deetlefs E, Peter J, Rajabally M, Rosa J, van Zyl J, Wright J, Cheon J, Jang B, Kim J, Kang S, Kim D, Kim T, Kim Y, Lee J, Lee K, Park D, Song G, Arguelles Arias F, Castro Laria L, Echarri Piudo A, Garcia Lopez S, Hernandez Ramirez V, Martin Arranz M, Varela Trastoy P, Vera Mendoza M, Lordal M, Biedermann L, Misselwitz B, Chang C, Chou J, Kuo C, Lin C, Tu C, Alkim H, Erzin Y, Soykan I, Kravchenko T, Tsarynna N, Vyshyvanyuk V, Ahmad T, Cummings F, Kapur K, Kaser A, Kent A, Parkes G, Patel K, Speight R, Steel A, Aberra F, Aguilar H, Al Bawardy B, Ananthakrishnan A, Barnes M, Beck K, Berkelhammer C, Boland B, Bullock J, Chiplunker A, Dalal R, Dalal S, Delgado B, DiGiovanna M, DuVall G, Freedland C, Friedenberg K, Gaidos J, Ginsburg P, Hassanein T, Higgins P, Hong J, Hou J, Huilgol V, Inamdar N, Kapur S, Kerman D, Levine H, Lodhia N, Loftus E, Mayoral J, McNeil D, Melmed G, Mushahwar A, Ojeas H, Patel B, Phillips R, Pouzar J, Sarles H, Schock J, Sedghi S, Shah N, Siddiqui J, Stokesberry D, Su L, Swaminath A, Verma D, Weber J, Younes Z, Zisman T. Risankizumab for Ulcerative Colitis. JAMA 2024, 332: 881-897. PMID: 39037800, PMCID: PMC11264075, DOI: 10.1001/jama.2024.12414.Peer-Reviewed Original ResearchClinical remission rateActive ulcerative colitisRemission rateUlcerative colitisInduction trialsMaintenance trialsClinical centersPhase 3 randomized clinical trialModerately to severely active ulcerative colitisSeverely active ulcerative colitisSafety of risankizumabTreatment of ulcerative colitisHistory of intoleranceMaintenance therapyClinical remissionClinical responseResponse to 1Intravenous treatmentRisankizumabAdverse event signalsConventional therapySubcutaneous treatmentFollow-upPlaceboAdvanced therapiesSaudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents.
Saadah O, AlAmeel T, Al Sarkhy A, Hasosah M, Al-Hussaini A, Almadi M, Al-Bawardy B, Altuwaijri T, AlEdreesi M, Bakkari S, Alharbi O, Azzam N, Almutairdi A, Alenzi K, Al-Omari B, Almudaiheem H, Al-Jedai A, Mosli M. Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents. Saudi Journal Of Gastroenterology 2024 PMID: 39215473, DOI: 10.4103/sjg.sjg_171_24.Peer-Reviewed Original ResearchInflammatory bowel diseaseSociety of Clinical PharmacyAdolescents aged 6Saudi Ministry of HealthMinistry of HealthManagement of inflammatory bowel diseaseSaudi Gastroenterology AssociationSaudi Society of Clinical PharmacyPediatric inflammatory bowel diseaseClinical pharmacyGastroenterological AssociationAged 6Bowel diseaseSaudi MinistryGuideline statementsManagement of pediatric inflammatory bowel diseaseSaudi childrenConsensus guidanceAdolescentsChildrenSaudiSaudi societyHealthPharmacyDiagnosisInflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia.
AlDhneem H, AlMutairdi A, Attamimi M, Mosli M, AlAmeel T, Al-Bawardy B. Inflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia. Saudi Journal Of Gastroenterology 2024, 30: 260-265. PMID: 38841910, PMCID: PMC11379256, DOI: 10.4103/sjg.sjg_19_24.Peer-Reviewed Original ResearchInflammatory bowel diseaseGI fellowsElderly/frail patientsAssociated with higher confidenceExternal rotationInflammatory bowel disease knowledgePreventive health servicesMulticenter survey studyManagement of inflammatory bowel diseaseInflammatory bowel disease managementGastroenterology fellowsHealth servicesSaudi ArabiaFellows' confidenceDidactic sessionsMethods of trainingExtraintestinal manifestationsCounseling patientsIBD patientsBowel diseaseIBD managementPatientsPreference learning methodLow confidenceConfidenceA Rare Cause of Acute Pancreatitis
Alghaythi S, Al-Bawardy B, Almuhaidb A. A Rare Cause of Acute Pancreatitis. Clinical Gastroenterology And Hepatology 2024, 22: a27-a28. PMID: 38768674, DOI: 10.1016/j.cgh.2024.04.040.Peer-Reviewed Original ResearchRates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease
Petrov J, Al-Bawardy B, Alzahrani R, Mohamed G, Fine S. Rates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024, 59: 232-236. PMID: 38595134, DOI: 10.1097/mcg.0000000000002003.Peer-Reviewed Original ResearchUstekinumab dose escalationDose-escalation groupInflammatory bowel diseaseDose escalationC-reactive proteinEndoscopic healingEscalation groupClinical remissionNormalization of C-reactive proteinSteroid-free clinical remissionBowel diseaseSerum C-reactive proteinNormalization of serum C-reactive proteinMaintenance of remissionReal-world cohortProportion of patientsUstekinumab doseMean hemoglobinBaseline albuminRetrospective studyUstekinumabMale sexMultivariate analysisPrimary outcomeSecondary outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply